Sensei Biotherapeutics Inc (SNSE) - Total Assets
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) holds total assets worth $27.59 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SNSE net assets for net asset value and shareholders' equity analysis.
Sensei Biotherapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Sensei Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Sensei Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sensei Biotherapeutics Inc's total assets of $27.59 Million consist of 92.4% current assets and 7.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Sensei Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SNSE company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sensei Biotherapeutics Inc's current assets represent 92.4% of total assets in 2024, an increase from 69.2% in 2018.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, down from 35.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sensei Biotherapeutics Inc Competitors by Total Assets
Key competitors of Sensei Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sensei Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.81 | 8.84 | 4.16 |
| Quick Ratio | 5.81 | 8.84 | 4.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.35 Million | $42.66 Million | $15.25 Million |
Sensei Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sensei Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.50 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -39.0% |
| Total Assets | $45.36 Million |
| Market Capitalization | $11.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sensei Biotherapeutics Inc's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sensei Biotherapeutics Inc's assets decreased by 39.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sensei Biotherapeutics Inc (2018–2024)
The table below shows the annual total assets of Sensei Biotherapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $45.36 Million | -39.01% |
| 2023-12-31 | $74.37 Million | -37.17% |
| 2022-12-31 | $118.38 Million | -22.74% |
| 2021-12-31 | $153.22 Million | +615.07% |
| 2020-12-31 | $21.43 Million | +1660.72% |
| 2019-12-31 | $1.22 Million | -34.22% |
| 2018-12-31 | $1.85 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also off… Read more